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Abstract
Background: Movement disorders, particularly those associated with basal ganglia disease, have a high rate of comorbid neuropsychiatric illness.
Methods: We consider the pathophysiological basis of the comorbidity between movement disorders and neuropsychiatric illness by 1) reviewing the epidemiology
of neuropsychiatric illness in a range of hyperkinetic movement disorders, and 2) correlating findings to evidence from studies that have utilized modern
neuroimaging techniques to investigate these disorders. In addition to diseases classically associated with basal ganglia pathology, such as Huntington disease,
Wilson disease, the neuroacanthocytoses, and diseases of brain iron accumulation, we include diseases associated with pathology of subcortical white matter tracts,
brain stem nuclei, and the cerebellum, such as metachromatic leukodystrophy, dentatorubropallidoluysian atrophy, and the spinocerebellar ataxias.
Conclusions: Neuropsychiatric symptoms are integral to a thorough phenomenological account of hyperkinetic movement disorders. Drawing on modern
theories of cortico-subcortical circuits, we argue that these disorders can be conceptualized as disorders of complex subcortical networks with distinct functional
architectures. Damage to any component of these complex information-processing networks can have variable and often profound consequences for the function of
more remote neural structures, creating a diverse but nonetheless rational pattern of clinical symptomatology.
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Introduction
Movement disorders, particularly those associated with basal
ganglia disease, have a high rate of comorbid neuropsychiatric
illness.1 An early recognition of this fact can be found in
Huntington’s classic description of hereditary chorea, in which he
noted ‘‘a tendency to insanity and suicide’’ to be one of the ‘‘marked
peculiarities’’ of the disease.2 Following his lead, McHugh described
a triadic syndrome of ‘‘dyskinesia, dementia, and depression’’ in
basal ganglia disorders, drawing on examples from Huntington
disease (HD) and Parkinson disease in particular.3 Citing the seminal
work of Alexander et al,4 McHugh went on to propose that damage
to anatomically parallel but functionally distinct neural loops within
the basal ganglia was responsible for the diverse manifestations of his
syndrome. While aspects of McHugh’s remain pertinent today,
our understanding of the biology of neuropsychiatric illness in move-
ment disorders has advanced considerably in recent decades.5–12
This has been facilitated in part by developments in structural
and functional neuroimaging techniques, especially in the field of
magnetic resonance imaging (MRI) and positron emission tomo-
graphy (PET).
This paper draws on neuroimaging research specifically in relation
to hyperkinetic movement disorders, which, in their diversity, offer the
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opportunity to refine and extend McHugh’s ideas. We argue that what
unifies these disorders in terms of their common relationship to a range
of cognitive, emotional, and behavioral symptoms lies in altered
structure and function in subcortical loops and circuits with which
basal ganglia structures are often, but not always, associated. The core
neuropsychiatric syndromes of some of these disorders, such as HD
and the neuroacanthocytoses for instance, are very likely to involve
dysfunctional cortico-striatal circuits (Figure 1);11,13 other disorders,
such as dentatorubropallidoluysian atrophy (DRPLA) and the
spinocerebellar ataxias (SCAs), may involve additional dysfunction
within cortico-spinal and cortico-cerebellar circuits (Figure 2).10,12,14
Our revised model synthesizes McHugh’s observations with modern
pathophysiologic theories of cortico-subcortical circuits7–12 and finds
support in a number of studies correlating structural and functional
neuroimaging with the variable neuropsychiatric comorbidity of the
hyperkinetic disorders. We argue that our approach provides novel
explanations as to why certain psychiatric syndromes are more
common in certain diseases, and may in fact offer a framework within
which to hypothesize about the frequent comorbidity of psychiatric
symptoms in other neurological disorders.
Huntington disease
HD (Online Mendelian Inheritance in Man 613004) is an inherited
autosomal dominant condition defined by a pathological trinucleotide
repeat affecting the huntingtin (HTT) gene on the short arm of
chromosome 4. Its prevalence is estimated to fall between 4.1 and 7.5
per 100,000.15 The clinical onset of the disease is generally accepted as
the manifestation of motor symptoms. This commonly occurs in the
fourth or fifth decade, with an inverse correlation between age of onset
and number of pathological trinucleotide repeats on the largest
expanded allele.16
Neurosychiatric symptoms have long been associated with HD.2
Depression appears to be the most common psychiatric comorbidity,
with estimates of prevalence ranging from 33% to 69% of patients.17
This stands in contrast to the estimated lifetime prevalence of
depression in the general population of about 16.5%.18 While one
study found the rate of suicide to be up to eight times higher than that
of the general population in HD patients over the age of 50,19 a more
recent finding is that depressive symptoms decline with illness stage,20
a discrepancy that may be due to supervening of depressive symptoms
by cognitive impairment in the later stages of the illness. Mania and
psychosis are less common in HD, with estimates of prevalence
ranging from 3–12% and 5–10%, respectively,21 which still stands in
contrast to the estimated lifetime prevalence of up to 1% and 3%,
respectively, in the general population.22,23 Patients with an earlier age
of HD onset are at greater risk of psychosis.24 Formal cases of obsessive
compulsive disorder (OCD) have rarely been reported, against a
background prevalence of around 1.6% in the general population.18
Nevertheless, in one large study nearly one-quarter of patients
presenting to a specialist clinic for the first time demonstrated obsessive
or compulsive symptoms.25 Obsessive and compulsive symptoms have
also been associated with increasing stage of illness26 and greater
executive dysfunction.27
The classic neuroimaging finding in HD is atrophy of the caudate
and putamen with concomitant alterations in the ratios of frontal horn
to intercaudate distance and intercaudate to inner table distance.28,29
This gives the frontal horns of the lateral ventricles a characteristically
rounded or box-like appearance. T2-weighted MRI signal may also be
Figure 1. Prototypical frontal cortico-striatal circuit. Bidirectional arrows:
pathways with both afferent and efferent connections. Dotted lines: notional
connections. Solid lines: literal connections. Th: Thalamus. SN: Substantia nigra.
GP: Globus pallidus. Striatum: caudate nucleus and putamen.
Figure 2. Prototypical cortico-cerebellar circuit. Bidirectional arrows:
pathways with both afferent and efferent connections. Dotted lines: notional
connections. Solid lines: literal connections. Th: Thalamus. IO: Inferior olive.
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increased throughout the caudate, putamen, and globus pallidus due to
gliosis and iron deposition.30
Several studies have used diffusion tensor imaging (DTI) to
investigate changes in white matter connectivity in both patients
and presymptomatic carriers of HD. Most studies have demonstrated
disruption of multiple cortical and subcortical white matter tracts in
patients and carriers alike, with robust correlations with stage of illness
and selective cognitive and motor impairments.31–33 The origin of the
changes lies in neuronal destruction in specific regions of the caudate
and putamen.34,35
HD patients with depression have also been shown to exhibit
hypometabolism in orbitofrontal and inferior prefrontal cortex on
fluorodeoxyglucose (FDG)-PET compared with HD patients without
depression.36 These changes are associated with subcortical but not
cortical gray matter volume loss, suggesting that cortical functional
changes may arise secondary to subcortical structural changes.
We conclude that disruption to cortico-striatal circuits plays an
important role, not just in the motor manifestations of HD but also in
the cognitive and behavioral manifestations of the illness.13,37
Neuroacanthocytoses
The neuroacanthocytoses are a group of disorders characterized by
neuropsychiatric symptoms associated with spiculated red blood cells
in the peripheral circulation. While genetically diverse, the neuroa-
canthocytoses include such disorders as chorea acanthocytosis (ChAc),
McLeod syndrome (MLS), and Huntington disease-like 2 (HDL2),
each of which will be considered below.
Chorea acanthocytosis
ChAc (OMIM 200150) is a rare autosomal recessive disorder caused
by mutations in the VPS13A gene on chromosome 9q coding for the
membrane protein chorein.38,39 As in HD, ChAc causes neuronal
pathology that is most evident in the caudate and putamen, but can also
be seen the ventrolateral substantia nigra and globus pallidus.40 The
clinical onset of the disease is usually between the ages of 25 and 45 years.
The majority of ChAc patients experience neuropsychiatric
symptoms40,41 and these may precede overt neurological illness by
more than a decade.42,43 The most common psychiatric problem in
ChAc is OCD, which affects more than 50% of patients.43,44 A similar
proportion of ChAc patients develop a dysexecutive cognitive
syndrome, ultimately leading to a frontal-subcortical dementia with
associated impairments in memory and speed of processing.40,43,45
Schizophrenia-like psychosis is relatively uncommon, but a small
number of cases have been reported.46
Neuroimaging findings in ChAc typically include progressive and
marked atrophy of the caudate and putamen with a predilection for the
caudate head.47 On MRI there may be increased T2-signal in the
dorsal striatum48 and some researchers have observed cerebellar
atrophy49–51 and white matter changes involving the corpus
callosum.50 We note the cerebellar and changes with special interest,
given the potential role of cortico-cerebellar dysfunction in executive
cognitive impairment,10 which features prominently in this disease.
In a study of two 33-year-old monozygotic twins, accentuated right
hemispheric changes on MRI, FDG-PET and [(123)I]beta-(2beta-
carbomethoxy-3beta-(4-iodophenyl)tropane) Single Photon Emission
Computed Tomography correlated with more severe hyperkinetic
movements on the left.52 In twin 1, who was initially misdiagnosed
with schizophrenia, a significant difference in binding to presynaptic
dopamine transporters with marked reduction on the right was also
observed. The researchers proposed loss of caudate neurons may thus
predispose to psychosis due to the deleterious effect on both up- and
downstream information processing within adjacent frontostriatal and
striatolimbic pathways previously implicated in schizophrenia.53 A
similar mechanism may account for the prevalence of OCD in ChAc
given the established link between obsessive-compulsive and dysex-
ecutive symptoms and impairments in the lateral orbitofrontal loop
primarily centered on the caudate.54
McLeod syndrome
MLS (OMIM 300842) is an X-linked genetic disorder characterized
by weakly expressed or absent Kell red blood cell antigens,
acanthocytosis, and elevated creatine kinase levels. It is caused by
mutations in the XK gene and mainly affects males, although female
carriers can show mild symptoms.55 Clinical onset is usually between
the ages of 25 and 60 years, and up to 80% of patients demonstrate
neuropsychiatric comorbidity at some stage of their illness.56,57 Like
ChAc, the neuronal loss associated with MLS predominantly affects
the caudate and putamen,40,58,59 and neuropsychiatric symptoms not
uncommonly predate the neurological manifestations of the illness.56,60
Executive dysfunction is common in MLS and has also been
described in female carriers.57 A high prevalence of OCD-like
syndromes has been reported by a number of authors.61–64 Psychotic
disorders may be just as frequent, with cases of schizophrenia-like
illnesses being reported in which typical psychotic symptoms have
preceded the onset of chorea.56,63,65
Marked caudate atrophy and increased T2 signal in the lateral
putamen are common MRI findings in MLS.57,61,66,67 Reduced
striatal D2 binding has been reported in PET studies
67,68 along with
hypometabolism of the basal ganglia and frontal lobes66 and altered N-
acetylaspartate to creatine/choline ratios in the frontal and medial
temporal cortex and thalamus.69 The absence of cortical neuronal loss
on limited neuropathological studies59 is reminiscent of HD, and again
suggests that functional cortical abnormalities are secondary to striatal
neuron loss, presumably via the loss of mediating cortico-striatal
pathways.
Huntington disease-like 2
HDL2 (OMIM 606438) is an autosomal dominant disease caused
by a CTG expansion in the junctophilin-3 gene (JPH3) on chromo-
some 16q24.3.70,71 It is only found in patients of black African
ancestry.70
Only a small number of HDL2 cases with comorbid neuropsychia-
tric illness have been reported in the literature, but they are notable for
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the heterogeneity of associated symptoms, including depression,
anxiety, and psychosis, in addition to a frontal-dysexecutive syndrome
leading to dementia.72–75 While neuropsychiatric comorbidity appears
to be the rule rather than the exception in HDL2, it may differ from
the other neuroacanthocytoses in that neuropsychiatric symptoms
seem to be reported only after the onset of neurological illness.
In common with the other neuroacanthocytoses, neuroimaging
reveals significant atrophy of both the caudate and the putamen,
and to a lesser extent the substantia nigra and pallidum.71,76 The
association of deep structural brain changes with such a broad range
psychiatric symptomatology again illustrates the critical role of cortico-
striatal circuits in the behavioral manifestations of the illness.
Wilson disease
Wilson disease (WD—OMIM 277900) is an autosomal recessive
disorder characterized by a mutation in the ATP7B gene coding for a
copper transport protein, leading to copper deposition in multiple
organ systems. In the central nervous system (CNS), it particularly
affects the putamen and pallidum.77 While the initial presentation of
WD may be hepatic, neurological, or psychiatric, about half of all
patients have neuropsychiatric symptoms at a given time.78
Affective disorders appear to be the most common neuropsychiatric
illnesses in WD79–81 and often meet the criteria for bipolar disorder.82
Personality changes characterized by irritability and aggression are
also very common.81 While neurologically asymptomatic patients
rarely show cognitive deficits,83 those with neurological disease often
display a range of difficulties, including impairments of executive
function, memory, and visuospatial processing.78,84,85 Psychosis is
relatively uncommon81,86 although cases of delusional disorder have
been reported.87,88 OCD has only been reported only once in
association with WD,89 which is surprising given the high rate of OCD
in other basal ganglia disorders, but may be hypothesized to reflect
some sparing of the caudate relative to illness such as HD and ChAc.
About half of patients with WD demonstrate basal ganglia
hypodensity on computed tomography (CT)90 and virtually all show
abnormalities on MRI.91 Characteristic features may include T2
hyperintensities within the lenticular nuclei, ventrolateral thalamus,
and hypothalamus, probably due to the paramagnetic effect of copper
and iron deposition within these structures.92 T2 hyperintensities in
the tegmentum often spare the red nuclei and medial margins of the
parts reticulta and superior colliculi, giving rise to the so-called ‘‘face of
the giant panda’’ sign.93
FDG-PET typically shows hypometabolism in the lenticular
nuclei,94 and in one study 19 of 25 patients examined by 99mTc-
ethyl-cysteinate dimer (ECD) SPECT exhibited diffuse or focal
hypoperfusion affecting the superior frontal, prefrontal, parietal, and
occipital cortices, the temporal gyri, caudate, and putamen.95 The fact
that the primary pathology associated with this disease is to be found in
the basal ganglia once again suggests that proximal damage to
components of cortico-subcortical circuits may have profound effects
on distal brain function, such as cognition and emotion.
Neurodegeneration with brain iron accumulation
Neurodegeneration with brain iron accumulation (NBIA) encom-
passes a group of genetically diverse disorders characterized by
neuronal death secondary to brain iron deposition. In the adult
population, NBIA includes pantothotenate kinase-associated neurode-
generation, aceruloplasminaemia, and neuroferritinopathy.
Pantothenate kinase-associated neurodegeneration
Pantothotenate kinase-associated neurodegeneration (PKAN—
OMIM 234200) is a rare autosomal recessive disorder caused by
mutations in the PANK2 gene. There are two main phenotypes. In its
classic form, PKAN is characterized by a severe and rapidly
progressive hyperkinetic movement disorder with an onset in the first
decade leading to complete loss of ambulation. A second, atypical form
exists that is characterized by a less severe and less rapidly progressive
movement disorder with an onset in the second to third decade.96 Both
phenotypes are associated with additional neurological symptoms
including dysarthria, dystonia, and cortico-spinal abnormalities.96
Cognitive decline is common in PKAN and tends to affect earlier-
onset patients more severely.97 It is not uncommon for cognitive
symptoms to predate motor signs98 and a pattern of impaired attention
and executive function is characteristic.99 Up to half of all patients
experience psychiatric problems, which include behavioral distur-
bances,96 OCD,100,101 tic disorders,102 psychosis,103 and depression.104
The neuroradiological hallmark of PKAN is the so-called ‘‘eye
of the tiger sign’’, which is characterized by bilateral areas of
hyperintensity within a region of hypointensity in the medial globus
pallidus on T2-weighted MRI.105 The low signal intensity is said to
result from excessive iron accumulation,106 with the central high signal
being attributed to gliosis and cavitation resulting in increased water
content.107 It is important to note that the sign is not specific to PKAN:
it can also been seen in other neurodegenerative disorders such as
cortico-basal ganglionic degeneration,108 progressive supranuclear
palsy,109 and neuroferritinopathy.107,110
In terms of functional imaging, a 99mTc-ECD SPECT study has
described regional hypoperfusion of the bilateral frontoparietal lobes,
lenticular nuclei, and ventriculus quartus in two siblings with adult-
onset disease and an identical PANK2 mutation.111 The cortical
metabolic findings are of particular interest given that PKAN is
classically defined by its subcortical pathology, which again suggests
that diaschesis via cortico-subcortical circuits plays an important role
in the genesis of clinical neuropsychiatric symptoms.
Aceruloplasminemia
Aceruloplasminemia (AC—OMIM 604290) is a rare autosomal
recessive disorder characterized by mutation in the ceruloplasmin (CP)
gene leading to iron deposition in multiple tissues due to impaired
ceruloplasmin ferroxidase activity.112,113 The major sites of CNS iron
deposition include the basal ganglia, cerebellar dentate nuclei, red
nucleus, thalamus, and hippocampus.114 AC occurs in just 1:2 million
non-consanguineous births and usually presents in the fifth or sixth
decade.115
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About half of all patients with AC present with cognitive
impairment116 and most progress to develop a subcortical dementia
characterized by executive dysfunction and cognitive slowing asso-
ciated with frontal hypometabolism.114,117,118 Only one case of major
psychiatric illness associated with AC has been reported, in the form of
a typical schizophreniform psychosis.118
MRI typically demonstrates marked T2 hypointensity correspond-
ing to regions of pathological iron deposition including those noted
above119–121 and can be used to quantify iron accumulation in vivo.122
Subtle hyperintensities of posterior white matter tracts have also been
reported, and subtle superficial cerebral and cerebellar cortical
hypointensities may be detectable when sequences sensitive to the
magnetic susceptibility effects of iron are used.121
Given the characteristic distribution of iron deposition in AC, the
primarily dysexecutive cognitive syndrome associated with the illness
may be the result of impairment to both cortico-striatal and cortico-
cerebellar circuits at the subcortical level.117
Neuroferritinopathy
Neuroferritinopathy (NF—OMIM 606159) is a rare autosomal
dominant disorder characterized by mutations in the ferritin light
chain (FTL1) gene. Patients commonly present in the fourth to sixth
decade with features of chorea (50%), dystonia (42.5%), or
Parkinsonism (7.5%).123 As with the other NBIA syndromes, the
globus pallidus is a common focus of iron deposition.124
In the small number of cases described, dementia and psychosis
have been the most common neuropsychiatric comorbidities. While
patients are generally said to have intact cognition until late in the
disorder,125 disinhibition and emotional lability may be the early
symptoms of a dysexecutive cognitive syndrome typically leading to a
frontosubcortical dementia.126,127 In one pedigree, akinetic mutism
was an additional late manifestation.128 Psychosis has also been
associated with NF: ataxia, rigidity-bradykinesia and neuroleptic-
responsive psychosis was reported in an adolescent patient with a
family history of schizophrenia,129 while another patient who
presented with severe generalized dystonia at the age of 22 years later
developed delusional jealousy.130
MRI typically demonstrates iron deposition and cavitation in the
basal ganglia with a characteristic loss of T2 signal. The red nucleus
and substantia nigra appear to be the first structures affected, with
subsequent involvement of the dentate nucleus, putamen, globus
pallidus, thalamus, caudate nucleus, and prefrontal cortex.126
Increasing R2* (the inverse of T2*) signal appears to correlate with
increasing severity of dystonia, and may be a clinically useful method
of tracking disease progression.131 Although functional imaging studies
are yet to be conducted, the anatomical distribution of injuries on
structural MRI would be expected to result in abnormalities in cotico-
striatal and cortico-cerebellar circuits, potentially correlating with the
predisposition of NF patients to psychosis and dementia.
Dentatorubropallidoluysian atrophy
Dentatorubropallidoluysian atrophy (DRPLA—OMIM 125370) is a
rare genetic disorder caused by a triplet repeat expansion of the
atrophin gene (ATN-1) on chromosome 12p13.31.132 It is most
prevalent in Asian pedigrees, and a review of cases within the Japanese
literature found psychosis to be the most common psychiatric
comorbidity, affecting about 10% of patients.133
Serial neuroimaging findings were reported in a Caucasian man
who was first scanned at the age of 38 years with a history of seizures,
tremor, ataxia, and dysarthria.134 Interval imaging showed progressive
atrophy of cerebellum and brainstem, with GRE and SWI sequences
demonstrating marked susceptibility effect throughout the cerebellar
hemispheres, vermis, and dentate nuclei. T2-weighted signal abnorm-
alities have also been documented in both the subcortical white matter
and brainstem white matter tracts in DRPLA.135,136 A neuroradiolo-
gical–pathological study of a father and son demonstrated signal
intensity changes in white matter were due to a marked loss of
myelinated fibers, while gray matter changes were largely due to a loss
of neuropil.137 Given the strong evidence that alterations to myelinated
fibers underpin psychotic symptoms in schizophrenia,138–140 it is not
surprising that psychosis is a common psychiatric comorbidity in this
group. It is difficult to explain why the degenerative changes of the
cerebellum and brainstem have not been associated with cognitive
symptoms, except to hypothesize that the potential link may not yet
have been investigated.
Spinocerebellar ataxias
The SCAs are a large family of autosomal dominant neurodegen-
erative disorders associated with subcortical dementia syndromes,141–144
depression, and personality change.145
Neuroimaging studies have mainly focused on SCAs 1 (OMIM
164400), 2 (OMIM 183090), 3 (OMIM 109150), 6 (OMIM 183086),
and 17 (OMIM 607136), and typically reveal one of three patterns of
atrophy: spinal atrophy (SA), olivopontocerebellar atrophy (OPCA),
and cortico-cerebellar atrophy (CCA).146 OPCA is typical of SCA 1, 2,
and 3 and is characterized by diffuse T2 and proton density signal
changes in the pons, middle cerebellar peduncle, and cerebellum in
association with atrophy of the cerebellum, brainstem, and cervical
spinal cord.147 CCA is associated with SCA 6 and 7, and MRI
typically shows atrophy of the cerebellar folia without signal change,
while the brainstem and spinal cord volume is preserved.148 A finding
that is believed to be specific to SCA3 is linear T2-hyperintensity along
the medial margin of the globus pallidus interna, and may be due to
degeneration of the lenticular fasiculus.149
In MRI studies using diffusion-weighted and diffusion tensor
imaging, both diffusivity and fractional anisotropy (FA) in the
brainstem and cerebellum was found to be decreased relative to
controls in SCA 1 and 2.150,151 Decreased FA may be more robustly
correlated with clinical severity in SCA 1 than measures of atrophy
using conventional MRI.152
One voxel-based morphometry study of SCA2 patients correlated
patterns of executive dysfunction with atrophy of the posterior
cerebellum, and coordinative dysfunction with atrophy of the anterior
cerebellum.153 Another study demonstrated a similar dissociation of
cognitive and motor functions in SCA17, as well as an inverse
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relationship between CAG repeat length and the rate of disease
progression.154
Both symptomatic and presymptomatic SCA-17 subjects imaged with
MRI and PET demonstrated atrophy of the cerebellum and caudate
nucleus and decreased glucose metabolism in the striatum, cuneus,
cingulum, and parietal lobes. In addition, PET was closely correlated
with both motor and cognitive performance as assessed by the Scale for
the Assessment and Rating of Ataxia, Unified Parkinsons Disease Rating
Scale, and Mini-Mental State Examination.11 C-raclopride PET
showed postsynaptic dopaminergic dysfunction within the putamen
and caudate nucleus that correlated with impairment of motor
performance.155
Taken together, the neuroimaging findings in a range of SCAs
would appear to support the hypothesis that the cortical dysfunction
associated with these disorders once again arises from a syndrome of
cortico-subcortical and cortico-cerebellar disconnection. That damage
to the cerebellum should so robustly translate into impairments of
higher cortical functions14,156 suggests that disrupted cortico-cerebellar
circuitry, in addition to the disrupted cortico-striatal and thalamo-
cortical circuitry, plays an important role in the genesis of
neuropsychiatric symptoms in these conditions.
Metachromatic leukodystrophy
Metachromatic leukodystrophy (MLD—OMIM 250100) is a severe
neurodegenerative metabolic disorder, also classified as a lysosomal
storage disorder. It is caused by deficient activity of arylsulfatase A
(ARSA) leading to accumulation of glycosphingolipid sulfatide and
progressive demyelination in the central and peripheral nervous
system.157 MLD is both genetically and phenotypically heterogeneous,
with a variable age of onset.158
Some MLD mutations are associated with predominant motor
presentations, others with cognitive and psychiatric features. Adult
homozygotes for p.P426L tended to present with gait disturbances
followed by choreoathetotic movements, dysphagia, dysarthria,
tremor, and nystagmus, whereas carriers of the less common p.I179S
mutation present primarily with psychosis.159 The cognitive changes of
MLD may resemble those of a generalized Alzheimer’s dementia, with
features that include amnesia, visuospatial dysfunction, attentional
deficits, and slowed processing speed.160–162
MLD is typically associated with the distinctive imaging findings of
diffuse periventricular and subcortical white matter hyperintensities
sparing subcortical U-fibers on T2-weighted MRI.163 The pattern of
white matter involvement is also characteristic with linear or punctuate
high signal radiating in the demyelinated white matter, sparing the
perivascular white matter, resembling ‘‘tigroid’’ or ‘‘leopard-skin’’.164
An increase in white matter myo-inositol on magnetic resonance
spectroscopy (MRS) supports demyelination in the pathophysiology of
MLD.165 A large case review has previously hypothesized that the
heavy burden of white matter disease in MLD, which particularly
affects the subfrontal white matter, may account for the unusually high
prevalence of psychosis in this disorder via disruptions to both
frontotemporal cortico-cortical and cortico-striatal circuitry.166
Niemann–Pick disease type C
Niemann–Pick disease type C (NPC—OMIM C1 257220, C2
607625) is a progressive neurodegenerative disorder caused by
disrupted intracellular sterol trafficking. Most cases are associated
with disruption of the NPC1 gene on 18q11,167 but around 5% are
associated with disruption of the NPC2 gene on 14q24.2.168 The
clinical manifestations of the disease are highly heterogeneous and may
appear any time between birth and late adulthood,169 although adult
patients typically present with ataxia, dystonia, chorea, vertical gaze
palsy, impaired cognition, and psychiatric illness.170
Psychosis is the most common psychiatric presenting complaint
among adult NPC patients.169,171 Presentations of depression, bipolar
affective syndromes and OCD have also been reported.172,173 While
up to 38% of NPC patients will first present with a psychiatric
syndrome, psychiatric sequelae—other than those associated with
dementia—in patients who first present with neurological symptoms is
regarded as rare.169
In one study of six adult NPC patients, VBM demonstrated gray
matter reductions particularly affecting the hippocampus, thalamus,
superior cerebellum, and striatum, regions where ganglioside accu-
mulation is greatest.170 On DTI, widespread reductions in fractional
anisotropy in major white matter tracts were also observed, with
subanalyses suggesting pathological contributions from both impaired
myelination and altered axonal structure. Other volumetric studies of
NPC patients have demonstrated reduced callosal area and thick-
ness174 and increased pontine-to-midbrain ratio175 in correlation with
duration of illness, symptom score, and aspects of saccadic dysfunction;
and reduced left hippocampal volume in correlation with symptom
score and cognitive dysfunction.176 An FDG-PET study of two
monozygotic children over a 2-year period demonstrated diffuse
cortical hypometabolism initially in the medial frontal cortex that
progressed to severe bilateral hypometabolism of frontal, parietal, and
temporal cortices.177
These structural and functional imaging studies in NPC provide a
compelling model of disrupted cortico-cortical connectivity due to
diffuse and extensive white matter changes, and cortico-subcortical
and cortico-cerebellar disconnectivity secondary to direct gray matter
disruption in these key relay zones.
Discussion
While hyperkinetic movement disorders are heterogeneous in terms
of both their neuropathology and neuropsychiatric comorbidity,
observations from neuroimaging studies suggest they share some
common neural circuit bases in association with complex forms of
cognitive, emotional, and behavioral dysfunction. By synthesizing a
modern model comprising cortico-striatal-pallido-thalamic and cor-
tico-cerebellar circuits7–12 with that of McHugh, we argue that
damage to certain strategic components of these circuits provides
unifying explanation for the apparently disparate functional manifesta-
tions of these disorders. The argument proceeds as follows:
Firstly, several neuropsychiatric syndromes are especially prevalent
across hyperkinetic movement disorders: executive dysfunction and
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subcortical dementia, affective disorders including OCD, and
psychotic disorders including schizophrenia-like syndromes. Many of
these neuropsychiatric disorders have been independently associated
with particular patterns of cortical dysfunction and dysfunction
ascribed to particular cortico-subcortical circuits. For instance, it
appears that early damage to the striatum strongly predisposes to
OCD.54 The caudate in particular is recognized as a point of origin for
the lateral orbitofrontal loop, and OCD may arise as a consequence of
alterations to the normal neurodevelopment of this circuit.43 Cortico-
striatal and striato-limbic circuits are similarly implicated in the
pathophysiology of psychosis,178 and cortico-cerebellar circuits in the
cognitive abnormalities associated with schizophrenia.156,179
Secondly, almost all of the hyperkinetic movement disorders are
associated with neuron loss in the basal ganglia, and some are also
associated with neuron loss in subthalamic and cerebellar nuclei.
These nuclei can be conceptualized as connective hubs or crossroads4
for both higher and lower brain functions, and within particular
cortico-subcortical circuits.
Thirdly, the limited functional imaging studies that exist in this area
points towards a dissociation between changes in cortical volume and
changes in cortical function,36 suggesting that the cortical abnormal-
ities associated with these disorders may, in some circumstances, arise
secondarily to the loss of populations of subcortical neurons.
Alterations to cortico-subcortical (Figure 1) and cortico-cerebellar
(Figure 2) circuitry constitute a mechanism for diaschisis that is
consistent with the manifestations of neuropsychiatric dysfunction
observed.
While certain psychiatric syndromes may be more or less common
in the hyperkinetic disorders, their heterogeneity also serves to provide
some evidence of the involvement of cortico-subcortical circuitry:
although the main circuits may be functionally distinct and subserve
different motor, cognitive, and emotional behaviors,4 they are not
anatomically separate; rather, they are parallel loops connected by
white matter tracts converging at certain strategic hubs, such as the
striatum, pallidum, thalamus, and cerebellum.7–12 Consequently, these
circuits interact in the striatum and other hubs to modulate each
other’s output,180 leading to symptoms across a broad range of
domains. The strategic vulnerability of cortico-subcortical circuitry
at multiple sites in the network may be a key factor in the
pathophysiology of these disorders.181
In the case of the hyperkinetic disorders with pathology more
strongly rooted in the basal ganglia (such as HD and the
neuroacanthocytoses), there is persuasive clinical and neuroimaging
evidence of remote functional pathology detectable at the level of both
white matter tracts and cortex. On the other hand, disorders associated
with primary white matter pathology, such as MLD, clearly exert a
strong functional influence on their proximal gray matter connections.
This paper also extends the model of cortico-subcortical dysfunction to
include nuclei in the cerebellum and brainstem, with similar
observations to be made for subthalamic diseases such as DRPLA
and the SCAs. Finally, those diseases in which cortico-subcortical loops
are affected very selectively (such as HD or MLD) appear to
demonstrate more robust associations to severe neuropsychiatric
illness than those that are affected more diffusely (such as WD and
NBIA).
McHugh proposed a triadic model of basal ganglia disorders
characterized by symptoms of dyskinesia, dementia, and depression.
His original hypothesis was that these disparate syndromes could be
accommodated by virtue of shared anatomical pathology affecting
functionally distinct subcortical loops. Our argument is that McHugh’s
acknowledgement of depression must be extended to include a broader
range of psychiatric syndromes associated with the cognitive-emotional
domains subserved by such circuits, and that his understanding of
dyskinesia must be extended to include a broader range of motoric
dysfunction
We would also like to suggest that a neurodevelopmental model may
help scaffold an understanding of the relative preponderance of these
conditions at different stages of illness. For instance, it is generally the
case that disorders known to be associated with departures from a
normal neurodevelopmental trajectory tend to present with early
neuropsychiatric illness such as OCD and schizophreniform psychosis.
The disruption to crucial late neurodevelopmental processes by young-
onset neurodegenerative disorders may thus result in neuropsychiatric
syndromes that would otherwise tend to present in adolescence or
early adulthood.182 In contrast, disorders that are associated with
degeneration of the mature brain, and which result in cognitive decline
or frank dementia, tend to be those which present later. One possible
exception to this principle is the early appearance of executive
dysfunction, which may be detectable in carriers and presymptomatic
individuals long before the onset of clinical disease. Executive function
may be a particularly cognitive vulnerable faculty given its phylogen-
etically more recent origin; this may also, however, reflect the rich
interconnectedness between frontal cortex and subcortical gray matter,
with disorders that either diffusely affect connecting structures or
specifically impact basal ganglia structures showing a predilection for
impairments in executive function.
In conclusion, we suggest that an expanded version of McHugh’s
model incorporating modern models of cortico-subcortical circuitry7–12
can be extended beyond diseases of the basal ganglia to encompass a
wide range of neurodegenerative disorders affecting cortico-subcortical
loops. Damage to any part of these complex information-processing
systems—including cortical grey mater, subcortical white matter, or
subcortical gray matter nuclei—can have variable and often profound
consequences for the function of more remote neural structures,
creating a diverse but nonetheless rational pattern of clinical
symptomatology.
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